Health Trials

Single or Repeat Zoledronate Versus Alendronate Following Denosumab (EUROpean Denosumab Effects Consolidation Study)

ConditionOsteoporosis, Postmenopausal
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age50-85
Sponsor424 General Military Hospital

About this trial

A 24-month prospective, open-label, randomized, multicenter, multinational, non-inferiority pragmatic clinical trial evaluating zoledronate single or double infusion versus oral alendronate following denosumab

Eligibility criteria

Qualifiers

None

Disqualifiers

a bone disease other than postmenopausal osteoporosis

use of medications other than bisphosphonates or SERMS affecting bone metabolism during the last 12 months before entering the study

creatinine clearance <60 mL/min/1.73 m2

liver failure

Trial design

Treatments tested in this trial

  • Zoledronate or Alendronate

Treatment groups

125 Participants
are divided into 3 treatment groups

Locations

9
France
Univ. Lille, CHU Lille Lille France
Greece
, KAT General Hospital14561, Athens Greece
251 Hellenic Airforce and VA General Hospital11525, Athens Greece
First Department of Propaedeutic and Internal Medicine, Medical School, National and Kapodistrian University of Athens11527, Athens Greece

Sponsors and collaborators

424 General Military Hospital

Lead sponsor

Source ClinicalTrials.gov